糖尿病神经缺血性足部伤口伴或不伴伤口靶向血运重建的愈合:一项8年前瞻性双中心注册研究的初步观察
该前瞻性双中心注册研究纳入167例糖尿病伴慢性肢体威胁性缺血(Rutherford 5级)和足部伤口(Wagner 2-4级)患者共194条肢体,比较血管体导向伤口靶向血运重建(WTR)与间接血运重建(IR)的临床疗效。结果示WTR组1年伤口愈合率70%,WTRc组54%,IR组20%(p=0.011),WTR组愈合时间更短,但无截肢生存率不受策略影响。
要点
- WTR组1年伤口愈合率70%,显著高于IR组20%(p=0.011)。
- WTR组平均愈合时间6.8个月,短于IR组9.8个月(p=0.001)。
- WTR与IR组间主要肢体不良事件和保肢率有差异,但无截肢生存率无差异。
核心结论
- 在糖尿病慢性肢体威胁性缺血患者中,有意的伤口靶向血运重建可能改善伤口愈合,但未观察到主要肢体不良事件或保肢方面的一致获益。
- 当血管体导向血运重建失败时,间接血运重建仍是保肢的替代选择。
研究设计与样本
- 前瞻性双中心注册研究,2009年4月至2017年7月纳入167例糖尿病伴慢性肢体威胁性缺血(Rutherford 5级)和足部伤口(Wagner 2-4级)患者共194条肢体。
- 患者计划行初次膝下血管内治疗,优先尝试特定血管体源动脉再灌注,失败后依次尝试经侧支的局部血运重建(WTRc)和间接血运重建(IR)。
主要发现
- 194条肢体中176条(91%)再灌注成功,其中WTR 113条、WTRc 28条、IR 35条;整体血管体导向技术成功率为73%(141/194)。
- 平均随访10.9±0.7个月(范围3-12.5),1年内176条成功治疗肢体中102条(58%)伤口愈合。
- WTR组愈合79/113(70%),WTRc组15/28(54%),IR组7/35(20%),p=0.011。
- 平均愈合时间WTR组6.8±0.4个月,WTRc组7.9±0.6个月,IR组9.8±0.7个月(p=0.001)。
- 复发率WTR组18条(16%),WTRc组5条(18%),IR组6条(17%);WTR与IR及WTRc与IR比较显示血管体导向组瘢痕形成改善(p<0.05)。
临床怎么用
- 对于糖尿病神经缺血性足部伤口患者,可优先考虑血管体导向的伤口靶向血运重建以促进伤口愈合。
- 当血管体导向血运重建失败时,间接血运重建仍可作为保肢的替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To assess the clinical efficacy of endovascular angiosome-oriented wound-targeted revascularization (WTR) vs indirect (wound-indifferent) revascularization (IR) in diabetic patients with neuroischemic foot ulcers. Materials and Methods: Between April 2009 and July 2017, 167 diabetic patients (mean age 72.8 years; 137 men) with chronic limb-threatening ischemia (Rutherford category 5) and foot wounds (Wagner 2-4) in 194 limbs were prospectively registered and scheduled for primary infragenicular endovascular treatment. Specific angiosome source artery reperfusion sustained by patent foot arches or arterial-arterial connections was attempted initially. If this approach failed, topographic revascularization via available collaterals (WTRc) and IR were sequentially attempted. Results: Reperfusion was successful in 176 (91%) of 194 limbs (113 with WTR, 28 with WTRc, and 35 with IR); the global angiosome-oriented technical success (WTR and WTRc) was 73% (141/194). The mean follow-up was 10.9±0.7 months (range 3-12.5). Over 1 year, 102 (58%) of the 176 successfully treated limbs experienced wound healing [79/113 (70%) in the WTR group, 15/28 (54%) in the WTRc group, and 7/35 (20%) in the IR group; p=0.011]. The mean time to healing was 6.8±0.4 months in the WTR group, 7.9±0.6 months in the WTRc group, and 9.8±0.7 months in the IR group (p=0.001). Relapses were noted in 18 (16%) WTR limbs, 5 (18%) WTRc limbs, and 6 (17%) IR limbs. Comparison between WTR and IR and WTRc vs IR showed improved cicatrization in the angiosome-oriented groups (p<0.05). Major adverse limb events (MALE) and limb salvage were different between WTR and WTRc and between WTR and IR groups (p<0.05), while WTRc vs IR was not. Amputation-free survival was not influenced by the revascularization strategy (p=0.093). Conclusion: Wound healing in diabetic patients with chronic limb-threatening ischemia appeared to be improved by intentional wound-targeted revascularization, but no uniform benefit concerning MALE or limb preservation was observed. IR still represents an alternative for limb salvage in cases in which angiosome-guided revascularization fails.
引用
- Alexandrescu VA, Brochier S, Limgba A, et al. Healing of Diabetic Neuroischemic Foot Wounds With vs Without Wound-Targeted Revascularization: Preliminary Observations From an 8-Year Prospective Dual-Center Registry. J Endovasc Ther. 2019. PMID: 31709886. doi:10.1177/1526602819885131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。